MB-105 is currently being evaluated in an open-label, single-arm, multicenter Phase 2 clinical trial (NCT06534060) for patients with CD5-positive relapsed or refractory T-cell lymphoma (r/r TCL). Trial sites are currently enrolling across the continental United States.
This trial is specifically for TCL Patients
The Phase 1 trial (NCT03081910) at BCM continues to enroll patients with T-cell acute lymphoblastic leukemia (T-ALL) through physician referrals.
Enrollment for this trial will remain available for T-ALL patients.
